Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The companyâ€™s lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patientâ€™s refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.
Funding Rounds (2) - $191.2MUpdate
Multinational financial services company
Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35...
LSP (Life Sciences Partners) is a leading independent European investment firm, providing...
Since 1974, Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build...
Private Equity Bank
Independent investment company
debt and equity financing
Veedijk 58 1004